ALXO - Company ID 0001810182
The table below shows ALX ONCOLOGY HOLDINGS INC's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $13.61M | $17.44M | $18.02M | $23.89M | $26.47M | $34.65M |
| SG&A |
ALX ONCOLOGY HOLDINGS INC reported annual revenue of $0.00 for fiscal year 2022. Over the 5 fiscal years shown, annual revenue declined from $2.07M (FY 2018) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $5.36M |
| $5.09M |
| $5.45M |
| $7.93M |
| $6.10M |
| $6.87M |
| Operating income | -$18.97M | -$22.53M | -$26.65M | -$31.82M | -$32.57M | -$41.52M |
| Income tax | - | - | - | - | - | - |
| Net income | -$17.93M | -$22.14M | -$25.95M | -$30.75M | -$30.71M | -$39.40M |
| EPS (diluted) | -$0.17 | -$0.41 | -$0.49 | -$0.58 | -$0.58 | -$0.76 |